$0.860
-0.047 (-5.49%)Zum Schluss
DRMA-News
DRMA-Events
Dermata Therapeutics Announces Positive Clinical Results for Tome Foundational Treatment
Dermata Therapeutics announced positive topline results from its recently completed cosmetic clinical study evaluating Tome Foundational Treatment, the Company's recently launched once-weekly skin renewal treatment. Tome Foundational Treatment is now available for purchase at www.tomeskincare.com either as a one-time purchase of four weekly treatments or through a subscription program at a discounted price. Dermata's recently completed cosmetic clinical study consisted of 31 participants in an open label study of Tome Foundational Treatment. Participants applied Tome Foundational Treatment one time per week for four weeks and were evaluated by an investigator at multiple timepoints throughout the study on endpoints including fine lines, hyperpigmentation, dark spots, smoothness, firmness, radiance, and overall appearance. Participants also completed self-evaluations after four treatments.
Selling Stockholders Plan to Sell Up to 6.92M Shares
This filing relates to the offer and sale from time to time by the selling stockholders of up to 6.92M shares of common stock. The company is not selling any shares under this prospectus and will not receive any of the proceeds from the sale of shares by the selling stockholders.
Dermata Therapeutics Officially Launches Tome Foundational Treatment
Dermata Therapeutics announced the official commercial launch of the Tome Foundational Treatment, the first product available for purchase under the Company's Tome skincare brand. The Foundational Treatment is now available for immediate purchase at www.tomeskincare.com, either as a one-time purchase or through a monthly subscription at a discounted price.
Dermata Therapeutics Opens Preorders for Tome Foundational Treatment
Dermata Therapeutics announced that Tome Foundational Treatment, the Company's first direct-to-consumer skincare product, is now open to preorders. The Tome Foundational Treatment is expected to start shipping on August 25, 2026.
Dermata Therapeutics Announces Launch of First Skincare Product on August 25, 2026
Dermata Therapeutics announced that Tome Foundational Treatment, the Company's first direct-to-consumer skincare product, is planned to launch on August 25, 2026, with those on the waitlist getting early access to preorder. The launch of the Foundational Treatment represents a significant milestone in Dermata's strategic evolution toward becoming a consumer-focused, revenue-generating, skincare company. Tome is built around the concept of bringing professional-grade solutions to the homes of skincare enthusiasts. The brand is designed to address growing consumer demand for accessible skincare that incorporate the science and efficacy associated with professional treatments, while fitting seamlessly into weekly routines.
Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.